Literature DB >> 14985465

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Michael Zimmer1, Darrell Doucette, Naila Siddiqui, Othon Iliopoulos.   

Abstract

The von Hippel-Lindau tumor suppressor protein (pVHL) is a substrate receptor for the mammalian SCF-2 E3 ubiquitin ligase complex that targets several substrates for ubiquitination and proteasomal degradation. Among these targets are the alpha-regulatory subunits of the hypoxia-inducible factor (HIF). VHL-/- cells constitutively overexpress hypoxia-inducible genes through both transcriptional and posttranscriptional mechanisms and form tumors when injected into nude mice. Reintroduction of pVHL into VHL-/- cell lines restores normal oxygen-dependent regulation of these genes and suppresses tumor formation in the mouse xenograft assay. We report here that short hairpin RNA-mediated inactivation of HIF phenocopies the effects of pVHL reintroduction with respect to decreased expression of hypoxia-inducible genes, decreased ability to promote vascular endothelial cell proliferation in vitro, and tumor growth suppression in vivo. In addition, HIF inactivation abrogated the cellular response to hypoxia, indicating that HIF is the only pVHL target required for this response. These data suggest that deregulation of hypoxia-inducible genes in VHL-/- cells can be attributed mainly to deregulation of HIF and validate HIF as a therapeutic anticancer drug target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985465

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  105 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 2.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

3.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

4.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

5.  The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.

Authors:  Qin Yan; Steven Bartz; Mao Mao; Lianjie Li; William G Kaelin
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

6.  Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

7.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Authors:  Eijiro Nakamura; Paula Abreu-e-Lima; Yasuo Awakura; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Hirokazu Kotani; Toshiaki Manabe; Guo-Jun Zhang; Keiichi Kondo; Vānia Nosé; William G Kaelin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 8.  Molecular biology of renal cell carcinoma.

Authors:  Begoña Mellado; Pere Gascón
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

9.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  Human cancers converge at the HIF-2alpha oncogenic axis.

Authors:  Aleksandra Franovic; Chet E Holterman; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.